MicroPort Orthopedics and Pixee Medical Expanded Partnership and Combined Demo at AAHKS

MicroPort Orthopedics Evolution® Medial-Pivot Knee Implant and Pixee Medical Knee+* platform demo at AAHKS 2022

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, today announces the expansion of its partnership with Pixee Medical through the commercialization of its combined surgical solution in the United States. Utilizing Pixee Medical’s FDA-cleared augmented reality surgical application for assistance in total knee arthroplasty, the surgeon can achieve precision and control when implanting MicroPort Evolution® Medial-Pivot Knee Implant. This solution is currently being used in thousands of successful cases around the world including in Australia, Europe, and Asia.

The MicroPort Orthopedics Evolution® Medial-Pivot Knee Implant delivers a high degree of stability and motion, leading to increased patient satisfaction1 and survivorship1. The Pixee Medical Knee+ is a patented platform designed to assist orthopedic surgeons to perform surgeries better and faster by providing real-time positioning of instruments, right in their field of view via smart glasses.

Combining MicroPort’s innovative devices with Pixee Medical’s platform is allowing patients, worldwide, access to surgery solutions integrating top of the class technologies.

This technology will be presented for the first time to U.S. surgeons at the Annual 2022 AAHKS meeting from November 3 to 6. Demos of Pixee’s technology will be available at MicroPort’s booth, #615. In addition, MicroPort will be hosting a symposium on Friday, November 4th, titled “Trends and Controversies in Hips, Knees, and the ASC,” where surgeon leaders will be discussing advances in arthroplasty.

“After much success around the world, we are excited to bring Pixee’s transformative technology to the United States for continued efficiency and precision of our device systems,” said Rob Cripe, Chief Commercial Officer at MicroPort Orthopedics. “Our mission at MicroPort is to help the patient achieve Full Function, Faster® – and the enhanced precision and efficiency this technology provides will help ensure this happens.”

“Combining MicroPort’s innovative devices and our platform is allowing patients, worldwide, access to surgery solutions that provide them with a faster recovery,” said Sébastien Henry, CEO at Pixee Medical. “Companies partnering in this orthopedic ecosystem are providing options to patients that weren’t available before now to improve their recovery and overall quality of life.”

MicroPort Orthopedics offers products and techniques to help patients receiving total hip and knee replacements achieve Full Function, Faster®. For more information, visit www.microportortho.com.

*MicroPort is acting as a distributor for these products and not as a sales agent for Pixee Medical.

1. Based on a retrospective study of Advance® Medial-Pivot. Macheras GA et al A long term clinical outcome of the Medial Pivot Knee Arthroplasty System. Knee. 2017 Mar.; 24(2):447-453

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”